FDA warning letter
Issue date
31 Oct 2022
Issuing office
Center for Drug Evaluation and Research | CDER
Posted date
8 Nov 2022
Subject
CGMP/Finished Pharmaceuticals/Adulterated
Products & Services
Abraxis Bioscience
Manufacturer
Warning letter
Sites
United States of America